Shhhh.....There's a New T-Cell Strategy
This opinion piece presents the opinions of the author. It does not necessarily reflect the views of BioSpace.
Cancer treatments continue to attract big venture bucks, from Cullinan's "don't be afraid to fail early" approach to Janpix's focus on STAT proteins to Forty Seven's clinical progress around CD47 antibodies. But what are the ever-interesting Peter Thiel and Sean Parker pursuing? Millions have been flying into a company called 3T Biosciences, which for now remains in deep stealth mode. Rumors have it the company is focused on something around T cell immunotherapy, but given this has become a rather broad and crowded field, that doesn't say too much.
Here's a roundup of these stories and other top financial news from the past month.
- Cullinan Oncology Emerges With $150M and a Roster of All-Star Biotech Scientists
- Janpix Launches With $22 Million and Will be Helmed by Ex-Boehringer Ingelheim Exec
- Silicon Valley Billionaires are Quietly Backing This Stealth Immunotherapy Startup
- Forty Seven Bags $75M, Bringing in a Total of $150M in Venture Capital
- Heads Up Biotechs: Illumina Ventures Closes $230M Fund
Read More From Karl Thiel:
Novartis Has Set a Tricky Precedent in Gene Therapy